Novel approaches to lipid lowering: what is on the horizon? (Q34188842)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11256846%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

review article

1 reference

title

Novel approaches to lipid lowering: what is on the horizon? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11256846%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

author name string

W V Brown

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11256846%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

language of work or name

English

0 references

publication date

1 March 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11256846%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Cardiology

5 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11256846%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

87

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11256846%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

5A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11256846%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

23B-27B

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11256846%20AND%20SRC:MED&resulttype=core&format=json

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

5 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901452-7

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901452-7

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901452-7

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901452-7

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901452-7

Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901452-7

Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin Rosuvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901452-7

Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901452-7

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901452-7

Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901452-7

Triglyceride as a risk factor for coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901452-7

Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901452-7

The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901452-7

Inhibitory effect of TS-962 on the formation of early atherosclerotic lesions in high fat-fed hyperlipidemic hamsters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901452-7

A target for cholesterol absorption inhibitors in the enterocyte brush border membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901452-7

Intestinal absorption of cholesterol is mediated by a saturable, inhibitable transporter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901452-7

10.1016/S0002-9149(01)01452-7

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11256846%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference